Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 5/20 | 0.37 |
| ▸ | TET3 | O43151 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9197945 | 0.76 | — | — | |
| SCHEMBL3183131 | 0.74 | — | — | |
| SCHEMBL14328730 | 0.74 | CYP2C19 (0.37) | CYP2C19HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL426229 | 0.73 | — | — | |
| SCHEMBL28445679 | 0.73 | CYP2D6 (0.47) | TET2TET3TET1CYP2C19GRIK1 | |
| SCHEMBL23879906 | 0.72 | — | — | |
| SCHEMBL14117192 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL9127361 | 0.70 | — | — | |
| SCHEMBL4957174 | 0.70 | — | — | |
| SCHEMBL2112190 | 0.69 | CYP2C19 (0.42) | CYP2C19HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947402-B2 | Solder mask inkjet inks for manufacturing printed circuit boards | AFGA-GEVAERT NV (BE) | 2021-03-16 | — | — | US | disclosed |
| EP-3321331-B1 | SOLDER MASK INKJET INKS FOR MANUFACTURING PRINTED CIRCUIT BOARDS | AGFA GEVAERT (BE) | 2020-10-21 | — | — | EP | disclosed |
| US-10351540-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351540-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208564-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208564-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208564-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | SABILA BIOSCIENCES LLC (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2018087059-A1 | SOLDER MASK INKJET INKS FOR MANUFACTURING PRINTED CIRCUIT BOARDS | AGFA-GEVAERT N.V. (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246444-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | EGFR, BRCA1, PTPRJ | TET2 2199/4885TET3 1998/4885TET1 721/4885 |
| US-20180208564-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | EGFR, BRCA1, PTPRJ | TET2 2199/4885TET3 1998/4885TET1 721/4885 |
| US-10351540-B2 | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | EGFR, BRCA1, PTPRJ | TET2 2199/4885TET3 1998/4885TET1 721/4885 |
| US-20180208584-A1 | 1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS | EGFR, BRCA1, PTPRJ | TET2 2199/4885TET3 1998/4885TET1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.